SYDNEY, May 18, 2015 /PRNewswire/ -- US-Australian drug
discovery and development company, Novogen Limited (ASX:NRT;
NASDAQ:NVGN), announced today that company CEO, Dr Graham Kelly, will be a presenting company at
Asia Biotech Invest 2015 May
20-21.
The Novogen presentation is at 10.00
am May 20 at the Sheraton
Hotel and Towers, Hong Kong.
The event is co-delivered by AusBiotech and Beacon Events, and
supported by partners including ChinaBio Group, HKBio, ASX and
Austrade.
Information about the program, speaker line up and spotlight
company presentations is available at www.asiabiotechinvest.com
Novogen CEO, Graham Kelly, said,
"This week represents our inaugural exposure of the Company to the
Asian investment market. A review of our share registry has
revealed a growing and significant level of shareholding out of
Asia, so the conference presents a
timely opportunity to start highlighting the Novogen story to this
enormous investment market. The conference presentation will be
accompanied by a road-show to institutional investors in
Hong Kong. With our need for funds
well on the way to being satisfied, it is now a case of
highlighting the investment opportunity by on-market buying in the
Company's two first-in-class technology platforms."
About Novogen
Novogen is a public, Australian-US drug development company
whose shares trade on both The Australian Securities Exchange (NRT)
and NASDAQ (NVGN). The Novogen group includes US-based, CanTx Inc,
a joint venture company with Yale
University. Novogen has two drug technology platforms
yielding drug candidates that are first-in-class with potential
application across a broad range of degenerative diseases. In the
oncology field, the ultimate objective is to see both drug
technologies used in combination as first-line therapy across most
forms of cancer, with the objective of preventing tumor recurrence.
This objective is based on a strategy of achieving comprehensive
destruction of the full hierarchy of cells within a tumor with the
super-benzopyran technology platform killing the tumor-initiating
cells and the anti-tropomyosin technology, combined with vinca
alkaloids, to deliver a potent chemical debulking effect on their
daughter cells.
For more information, please visit www.novogen.com
Corporate
Contact
Dr. Graham
Kelly
Executive Chairman
& CEO
Novogen
Group
Graham.Kelly@novogen.com
+61 (0) 2 9472
4101
|
Media
Enquiries
Prue Kelly
Media
Officer
Novogen
Group
Prue.Kelly@novogen.com
+61 (0) 2 9472
4101
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/novogen-to-present-at-hong-kong-investor-conference-300084597.html
SOURCE Novogen Ltd